Texas Tech University Health Sciences Center at Lubbock Hematology and Medical Oncology

Topics

• Renal cell carcinoma treatment 112
• CAR-T cell therapy research 22
• Prostate Cancer Treatment and Research 16
• Bladder and Urothelial Cancer Treatments 14
• Hematopoietic Stem Cell Transplantation 13
• Cancer Immunotherapy and Biomarkers 12
• COVID-19 Clinical Research Studies 12
• Multiple Myeloma Research and Treatments 11
• Acute Myeloid Leukemia Research 8
• Lymphoma Diagnosis and Treatment 6
• SARS-CoV-2 and COVID-19 Research 6
• Advanced Breast Cancer Therapies 4

Most cited

1. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

   The New England journal of medicine · 2021 · 1,467 citations · Thomas Hutson

2. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 158 citations · Thomas Hutson

3. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.

   The Lancet. Haematology · 2021 · 305 citations · Muhammad Abid

4. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.

   Blood · 2021 · 170 citations · Muhammad Abid

5. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

   The Lancet. Oncology · 2023 · 140 citations · Thomas Hutson

6. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

   Journal for immunotherapy of cancer · 2022 · 130 citations ·